Scroll Top
LENZ Therapeutics Logo LENZ-Tx
LENZ Therapeutics
LENZ Therapeutics is a late-stage clinical company developing innovative ophthalmic pharmaceutical products that improve vision.  Our lead program is an aceclidine based eye drop designed to restore the loss of near vision associated with presbyopia.

Presbyopia is the gradual and inevitable loss of near vision
Research shows adults over 45 lose on average 1.5 lines of near vision every 6 years1
Most of us first start to notice this as…
  • We hold our phones farther from our eyes
  • Have difficulty reading a menu in a dimly lit restaurant

The first and only aceclidine-based eye drop with potential of providing all day seamless vision for the vast majority of presbyopes
Phase 3
  • Made possible by aceclidine, our novel active ingredient
  • Quickly achieved near vision for on demand needs with a long duration*
  • No impact on distance vision in standard and night conditions*
  • Potential for broadest target patient population
*Based on Phase 2 study

The Only Pupil Selective Miotic
Aceclidine is the active and new chemical entity in our lead drug
  • Unique mode of action
  • Targets iris sphincter for pinhole effect
  • Predominantly avoids ciliary stimulation preventing unwanted refractive errors
LENZ Therapeutics
Vision Expo West 2023

LENZ Therapeutics will be attending the annual Vision Expo West meeting in Las Vegas on Sep 28 – 30. Visit our booth during exhibiting hours on Thursday, Friday and Saturday!

MOD Live Meeting 2023

LENZ Therapeutics will be attending the MOD Live Meeting in Nashville. Join our presentation on Friday, Sep. 8 @5:15pm, and tabletop booth during exhibiting hours.

NMPA only JIXING Thumbnail
China NMPA Approves CTA of LNZ100 and LNZ101
LENZ Therapeutics is pleased to share that JIXING Pharmaceuticals, our partner for Greater China, has received approval of the Clinical Trial Application (CTA) for the Phase 3 clinical trial of LNZ100 and LNZ101 for the treatment of presbyopia in China.